Attomarker Diagnostics

21/07/2025

In the latest joint webinar with Dr Ben Sinclair, (GP & Founder of Dr Finlay’s Private Practice), Professor Andrew Shaw and Dr Sinclair discussed the latest advances in long COVID testing and treatment.

In the webinar, Professor Shaw also introduced the upcoming Tasso device, a new method of blood collection that will soon be available for the Attomarker COVID Antibody Spectrum Test. This upper-arm device offers an alternative to the existing finger-prick sample, making home testing more accessible and straightforward for patients.

Watch the full recording here: https://www.youtube.com/watch?v=VVtPXRyVzOc

08/07/2025

We're thrilled to announce the third webinar in our joint series, featuring Dr Ben Sinclair (GP & Founder of Dr Finlay’s Private Practice) and Professor Andrew Shaw (Founder of Attomarker).

Join us for this next instalment on Tuesday, 16th July 2025, at 6 PM BST.

In this session, we'll discuss the latest developments in long COVID testing and treatment, share real-world patient insights, and explore promising paths to recovery and personalised care.

What you'll gain from joining:
✅ Advances in long COVID testing: Updates on Attomarker’s rapid blood test and its insights into viral persistence.
✅ What we’ve seen in practice: Dr. Sinclair's new outcomes and tailored treatment approaches from recent patient cases.
✅ The latest in long COVID care: Discover emerging clinical pathways and support.
✅ Live Q&A: Your chance to ask questions directly to our international experts.
✅ Guidance for recovery: Practical next steps whether you're newly interested or on an ongoing journey.

This is a vital opportunity for patients, families, and professionals to gain clarity and practical guidance.

Register now: https://us06web.zoom.us/webinar/register/WN_GYq9YQA7RSmM2E7juSfHwQ #/registration

02/07/2025

New insights into long COVID patient types are emerging. In a clip from our latest 'Prof Talks' webinar, Professor Andrew Shaw elaborated on how our classification system distinguishes three primary categories of long COVID patients. He explained that clinicians can identify those who are immunocompromised with a sub-optimal antibody spectrum, those exhibiting a hyperimmune reaction, and a remaining group (approximately 25%) who appear as universal responders with no obvious characteristics from their antibody spectrum.

This insightful segment is from our last 'Prof Talks' webinar, where Professor Shaw specifically addressed long COVID in children and examined hyperimmune responses to long COVID. You can watch the full recording on our website or YouTube and join us for our next 'Prof Talks' webinar with Professor Andrew Shaw on Tuesday, 8th July 2025, at 6 PM BST, where we’ll discuss expert insights into long COVID and Attomarker’s advanced testing capabilities.

Register now to secure your place: https://zoom.us/webinar/register/WN_B3CvSikWRleg6nrvnxZ97w #/registration

30/06/2025

In a our latest 'Prof Talks' webinar, Professor Andrew Shaw discussed a scientific mechanism for hyperimmune responses, suggesting that messenger RNA from vaccines, if reaching cells beyond the injection site (such as heart cells), could lead to the production of spike proteins in those cells.

Professor Shaw explained that the immune system, in attempting to target these spike proteins, might subsequently learn to attack the host's own cells, leading to a hyperimmune response against native proteins alongside the viral spike. While acknowledging the complexity of proving such a direct link, he highlighted that the systemic distribution of vaccine mRNA within the body has been observed. This proposed mechanism opens avenues for further research into hyperimmune conditions and potential connections to vaccine-related injury.

Our last 'Prof Talks' webinar focused on long COVID in children and examining hyperimmune responses to long COVID, a session from which this clip is taken. You can watch the full recording on our website or join us for our next 'Prof Talks' webinar with Professor Andrew Shaw on Tuesday, 8th July 2025, at 6 PM BST, where we’ll discuss expert insights into long COVID and Attomarker’s advanced testing capabilities.

Register now to secure your place! https://zoom.us/webinar/register/WN_B3CvSikWRleg6nrvnxZ97w #/registration

25/06/2025

The mystery of long COVID continues to challenge us, what drives the lingering symptoms?
From our recent Prof Talks webinar, Professor Andrew Shaw explored the complexities of long COVID in children. His research specifically examines the fascinating and often challenging aspect of hyperimmune responses in young individuals affected by long COVID.

As Professor Shaw explains, the antibody spectrum test offers a crucial lens to understand the "host response" to SARS-CoV-2. By analysing an individual's immune reaction to 14 different SARS-CoV-2 variants, we can gain vital insights. This approach helps determine if the immune system effectively clears a specific variant or if an unusual immune response contributes to ongoing symptoms. Such detailed immune profiling is essential for comprehending the intricate relationship between a prior infection and the body's continued struggle to fully recover from long COVID.

You can watch the full recording on our website to gain further expert insights into these critical areas of research.

Join us for our next 'Prof Talks' webinar with Professor Andrew Shaw on Tuesday, 8th July 2025, at 6 PM BST. Register now to secure your place: https://zoom.us/webinar/register/WN_B3CvSikWRleg6nrvnxZ97w #/registration

24/06/2025

We are pleased to announce our next 'Prof Talks' webinar, offering expert insights into long COVID and the crucial role of advanced testing. As the "Nimbus" variant continues to emerge globally, understanding the latest developments and how they impact individuals is more vital than ever.

Join us on Tuesday, 8th July 2025, at 6 PM BST, for an informative session led by Professor Andrew Shaw, Founder and CEO of Attomarker. This webinar is a valuable opportunity to engage directly with our team and gain clarity on pressing questions surrounding long COVID.

During the discussion, we will cover:
✅ The very latest developments in understanding long COVID.
✅ The science underpinning Attomarker’s ongoing research and the performance of our advanced tests.
✅ Live answers to your questions during the session.

We are committed to providing clear, actionable information to our community. We believe this session will offer genuine insights and support.

Register here:
https://zoom.us/webinar/register/WN_B3CvSikWRleg6nrvnxZ97w #/registration

23/06/2025

This month we launched the Attomarker COVID Antibody Spectrum test in the USA
with a pilot of around 50 people. If you are in the USA and are impacted by long
COVID please could you spare less than 5 minutes to complete this short survey to
help us understand the needs of the long COVID community in the USA.

The link is: https://forms.gle/6RuvLBHjzEj3EQbSA.

We’d really value your input and would be grateful if you could share it with your network.

We are exploring how to better meet the needs of people managing long COVID in the USA and would really value your input. If you are living with long COVID symptoms, please take a few minutes to complete this short survey. Your insights will help inform our understanding and shape how we can better....

10/06/2025

When we told our community about our plans for a monoclonal antibody therapy trial for long COVID patients, a lot of people wanted to know more. Our search for philanthropy and getting our hands on the therapy continues, but if you are interested to know more about how research has informed our recommendations for the trial you can view our revised article on the Persistent Virus Theory:

The Immune Response to SARS-CoV-2 and Long COVID Long COVID is currently reported to affect as many as one in five individuals who have had a COVID infection in the UK, with each new SARS-CoV-2 infection adding to the risk burden of developing the debilitating Infection Associated Chronic Condition

05/06/2025

New findings from a study using data from the RECOVER Initiative, analysing over 225,000 paediatric electronic health records, reveal important differences in symptoms among children from diverse racial and ethnic backgrounds. The study included children diagnosed with or tested positive for COVID-19 between March 2020 and October 2022, comparing their health before and after infection. This research provides a deeper understanding of how long COVID manifests, moving beyond a one-size-fits-all approach.

Key findings indicate distinct symptom profiles based on ethnicity:
· Non-Hispanic Black children: Experienced more cognitive function problems.
· Hispanic children (with severe COVID-19): Showed higher rates of hair loss.
· Asian American and Pacific Islander children: More likely to experience fever and chills, and those with nonsevere COVID-19 faced a higher risk of post-infection illnesses, including POTS (Postural Orthostatic Tachycardia Syndrome).

These differences are not primarily biological, but instead reflect social, financial, and healthcare access factors. This research underscores the need for culturally competent and targeted screening and follow-up protocols. By acknowledging these disparities, we can not only improve early detection and management of long COVID symptoms, but also advance our understanding of the underlying pathophysiology, informing more precise and equitable care for all children.

We invite you to join our growing long COVID community and receive vital updates and insights. Connect with us to stay informed: https://attomarker.com/support/register/patient-registration/

28/05/2025

At the recent Polybio Symposium, Dr Michael Peluso reported on the Outsmart Long COVID trial, which used the antibody AER002 on long COVID patients. He confirmed negative results and highlighted a pattern of unsuccessful trials, including two antiviral studies alongside his own antibody trial.

Crucially, analysis using the COVID Antibody Spectrum test offered significant insights from the 36 trial participants. It indicated that 65% would have been suitable candidates for antibody therapy based on their specific antibody spectrum profiles. Conversely, 25% would not have been recommended for such treatment, and 10% were identified as hyperimmune – a status that could potentially increase risks associated with antibody therapy.

This underscores the vital need to integrate antibody profile insights into future trial designs, moving beyond sole reliance on the WHO's definition of persistent symptoms at 12 weeks. Indeed, our emerging classification framework may prompt a necessary re-evaluation of how we define and approach long COVID itself.

Join us for our upcoming webinar tomorrow, 29th May, 6 pm BST, where we will further explore long COVID in children and examine hyperimmune responses to long COVID.

Register now for the webinar: https://zoom.us/webinar/register/WN_KO7CuBfYTRCfqDQj4QeY1g